# Emergent BioSolutions clinical trials: 47 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 47 trials with Emergent BioSolutions as lead sponsor, 5 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Emergent BioSolutions: 47 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/emergent-biosolutions

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 47
- Recruiting or not yet: 5
- Read on: November 19, 2026

## Trials

The 25 newest of 47, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| March 17, 2026 | NCT07478471 | Observational Study of Raxibacumab in Sporadic Cases of Systemic Anthrax | Emergent BioSolutions | Observational | Not yet recruiting | Infections, Bacterial | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07478471) |
| December 8, 2025 | NCT07268612 | Evaluation of Clinical Benefit and Safety Following CYFENDUS Administration for Post-Exposure Prophylaxis of Anthrax Disease. | Emergent BioSolutions | Observational | Not yet recruiting | Anthrax | 250 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07268612) |
| July 7, 2023 | NCT05935917 | Study Evaluating the Bioequivalence of Brincidofovir Form H and Form II Tablets in Healthy Adults | Emergent BioSolutions | Phase 1 | Completed | Smallpox | 44 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05935917) |
| May 17, 2022 | NCT05377255 | Pharmacokinetics (PK) and Safety of Multiple Doses of Intranasal Naloxone in Healthy Adults | Emergent BioSolutions | Phase 1 | Completed | Opioid Overdose | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05377255) |
| January 18, 2022 | NCT05194358 | Study of SIAN Nasal Spray in Healthy Adults | Emergent BioSolutions | Phase 1 | Completed | Cyanide Poisoning | 47 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05194358) |
| December 13, 2021 | NCT05155319 | Universal Influenza A Vaccine in Healthy Adults | Emergent BioSolutions | Phase 1 | Completed | Human Influenza | 27 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05155319) |
| December 2, 2021 | NCT05142306 | A COVID-19 Study to Evaluate Safety and PK of COVID-HIG Administered Through IM, SC, or IV Routes to SARS-CoV-2 Uninfected Adults | Emergent BioSolutions | Phase 1 | Completed | SARS-CoV-2 Infection | 23 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05142306) |
| December 10, 2020 | NCT04661839 | A COVID-19 Study to Evaluate Safety and Pharmacokinetics of COVID-HIGIV Administered in Healthy Adults | Emergent BioSolutions | Phase 1 | Completed | COVID-19 | 28 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04661839) |
| August 26, 2019 | NCT04067011 | Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study | Emergent BioSolutions | Phase 2 | Completed | Anthrax | 210 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04067011) |
| March 18, 2019 | NCT03877926 | VELOCITY: An Anthrax Vaccine Clinical Study | Emergent BioSolutions | Phase 3 | Completed | Anthrax | 3,689 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03877926) |
| August 10, 2018 | NCT03624946 | Study in Healthy Volunteers Evaluating Safety and Pharmacokinetics of Zika Virus Immune Globulin (ZIKV-IG) | Emergent BioSolutions | Phase 1 | Completed | Zika Virus Infection, Zika Virus Disease | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03624946) |
| June 26, 2018 | NCT03569553 | A Field Study Evaluating Clinical Benefit and Safety of AIGIV (ANTHRASIL®) in Inhalational Anthrax Patients | Emergent BioSolutions | Observational | Not yet recruiting | Inhalational Anthrax | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03569553) |
| June 26, 2018 | NCT03569514 | Observational Study Evaluating Clinical Benefit and Safety of AIGIV (ANTHRASIL®) in Patients With Systemic Anthrax | Emergent BioSolutions | Observational | Not yet recruiting | Anthrax | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03569514) |
| October 19, 2017 | NCT03315104 | Exploring Safety & Clinical Benefit of Anti-Influenza Immunoglobulin Intravenous in Hospitalized Adults With Influenza A | Emergent BioSolutions | Phase 2 | Completed | Influenza A H3N2, Influenza A H1N1 | 65 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03315104) |
| May 19, 2017 | NCT03160339 | A Study to Assess the Safety, Pharmacodynamics, and Immunogenicity of PXVX0047 | Emergent BioSolutions | Phase 1 | Terminated | Adenoviral Infection | 25 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03160339) |
| May 13, 2016 | NCT02771730 | Study to Evaluate the Safety and Immunogenicity of an Oral HIV Vaccine in Healthy, HIV-uninfected Adults | Emergent BioSolutions | Phase 1 | Terminated | Healthy Volunteer, HIV Vaccine | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02771730) |
| March 2, 2016 | NCT02696291 | Safety and Pharmacokinetics of UV-4B Solution Administered Orally as Multiple Ascending Doses to Healthy Subjects | Emergent BioSolutions | Phase 1 | Terminated | Viral Infection | 7 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02696291) |
| May 14, 2015 | NCT02443623 | VA-008 ACAM2000® Vaccination of Plasma Donors for the Production of VIGIV | Emergent BioSolutions | Phase 4 | Completed | Smallpox Vaccine Adverse Reaction | 3,032 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02443623) |
| January 15, 2015 | NCT02339155 | Effect of Raxibacumab on Immunogenicity of Anthrax Vaccine Adsorbed | Emergent BioSolutions | Phase 4 | Completed | Infections, Bacterial | 573 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02339155) |
| June 30, 2014 | NCT02177721 | Clinical Benefit and Safety of Raxibacumab in Patients With Symptomatic Inhalational Anthrax in a Mass Exposure Scenario | Emergent BioSolutions | Phase 4 | Not yet recruiting | Infections, Bacterial | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02177721) |
| February 12, 2014 | NCT02061358 | Study to Determine the Safety, Tolerability and Pharmacokinetics of UV-4B Solution Administered Orally in Healthy Subjects | Emergent BioSolutions | Phase 1 | Completed | Viral Infection | 64 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02061358) |
| February 5, 2014 | NCT02055183 | BT-010 Registry for the Evaluation of Safety and Clinical Outcomes in Patients Treated With Botulinum Antitoxin | Emergent BioSolutions | Observational | Completed | Botulism | 162 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02055183) |
| January 31, 2014 | NCT02051062 | BT-011 Pharmacokinetics of Botulism Antitoxin Heptavalent in Pediatric Patients | Emergent BioSolutions | Phase 4 | Enrolling by invitation | Botulism | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02051062) |
| November 8, 2013 | NCT01979406 | A Phase 1 Ascending Dose Study to Assess the Safety and Immunogenicity of Adenovirus Anthrax Vector Candidate Vaccines | Emergent BioSolutions | Phase 1 | Completed | Anthrax Infection | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01979406) |
| January 18, 2013 | NCT01770743 | A Phase 2 Safety and Immunogenicity Study for an Anthrax Vaccine Using 3 Schedules and Two Dose Levels | Emergent BioSolutions | Phase 2 | Completed | Anthrax | 168 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01770743) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 18 |
| Phase 1/2 | 1 |
| Phase 2 | 8 |
| Phase 2/3 | 1 |
| Phase 3 | 4 |
| Phase 4 | 4 |
| Observational | 11 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 35 |
| Terminated | 5 |
| Not yet recruiting | 5 |
| Enrolling by invitation | 2 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Anthrax | 14 |
| Smallpox | 7 |
| Bacterial Infections | 5 |
| Vaccinia | 4 |
| Influenza, Human | 3 |
| Virus Diseases | 3 |
| Inhalation anthrax | 3 |
| Lymphoma, T-Cell | 2 |
| Dengue | 2 |
| Arbovirus Infections | 2 |
| Flaviviridae Infections | 2 |
| Flavivirus Infections | 2 |
| Hemorrhagic Fevers, Viral | 2 |
| RNA Virus Infections | 2 |
| Botulism | 2 |
| COVID-19 | 2 |
| Pregnancy Complications | 1 |
| Congenital Abnormalities | 1 |
| Maternal Death | 1 |
| Obstetric Labor, Premature | 1 |
| Eclampsia | 1 |
| Pre-Eclampsia | 1 |
| Abortion, Spontaneous | 1 |
| Diabetes, Gestational | 1 |
| Pregnancy, Ectopic | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Diners in the United States](https://specstream.ai/data/businesses/diners/united-states)
- [Optometrists in the United States](https://specstream.ai/data/businesses/optometrists/united-states)
- [Apparel manufacturers in the United States](https://specstream.ai/data/businesses/apparel-manufacturers/united-states)
- [Furniture manufacturers in the United States](https://specstream.ai/data/businesses/furniture-manufacturers/united-states)
- [Records storage companies in the United States](https://specstream.ai/data/businesses/records-storage-companies/united-states)
- [Building contractors in the United States](https://specstream.ai/data/businesses/building-contractors/united-states)
